30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: Vexim

4Q14 revenue €2.9MM (~US $3.3MM), +44.5%

2014 revenue €10.3MM (~US $11.6MM), +68.5%


  • >8,000 SpineJack implants sold in 2014, +76% from 2013 (>17,000 since launch in late 2010)
  • Claims ~7% of European vertebral fracture market; expecting to capture substantial market share gains
  • Will focus on growth in high potential regions, like Latin America and Asia
  • Planning 2 new product launches in U.S. for 2015